Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

Core Viewpoint - INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, P.C., marking a significant step in its strategy to expand its fertility care centers across the United States [1][2]. Group 1: Acquisition Details - The purchase agreement follows the announcement made on November 27, 2025, regarding the intent to acquire Family Beginnings [2]. - Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the 12-month period ending September 30, 2025 [2]. - The total purchase price for the acquisition is $750,000, with $350,000 to be paid in cash at closing and $400,000 in preferred stock [4]. Group 2: Strategic Importance - The acquisition aligns with INVO's mission to enhance access to advanced fertility care and expand its operational footprint [3]. - Family Beginnings is recognized for its strong clinical reputation and offers a comprehensive range of reproductive services, including IVF and fertility preservation [3]. Group 3: Leadership and Integration - Dr. James Donahue will continue to lead Family Beginnings under a three-year agreement following the acquisition [4]. - The integration of Family Beginnings into INVO's operations is anticipated to build upon the existing foundation and further grow the practice in the local market [3].

Core Insights - INVO Fertility reported a strong financial performance in Q3 2025, with total revenue increasing by 23% year-over-year to $1,757,094, driven by higher patient volumes and enhanced marketing efforts [5][4] - The company achieved 18% organic growth across its clinics, attributed to increased patient flow and expanded telehealth capabilities [5][4] - The recent policy updates allowing employers to offer standalone infertility benefits are expected to further enhance access to IVF treatments, contributing to industry growth [5][4] Financial Highlights - Total revenue for Q3 2025 was $1,757,094, up from $1,433,151 in Q3 2024, marking a 23% increase [5] - Consolidated clinic revenue increased by 21% to $1,722,223 compared to $1,418,011 in the previous year [5] - The net loss for the quarter was $(2.6) million, compared to $(1.6) million in Q3 2024 [5] Operational and Strategic Highlights - The company is focused on strengthening organic performance and pursuing acquisition opportunities, with a pipeline of target clinics for potential acquisition [4] - INVOcell device revenue grew by 130% year-over-year, reflecting successful expansion initiatives and improved pricing strategies [5][4] - Operational efficiencies are being pursued through partnerships, such as with Heidi Health for AI-powered solutions [5][6] Management Commentary - The CEO emphasized the importance of organic growth and acquisition strategies in driving the company's mission to enhance patient access to fertility services [4] - The company is committed to operational efficiency to achieve profitability while expanding its services [6]

As filed with the Securities and Exchange Commission on October 10, 2025 Registration No. 333-290284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Wing Fung Alfre ...

Core Insights - INVO Fertility, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference, hosting a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3] Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [4] - The company's primary strategy includes building and operating "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device, which allows fertilization and early embryo development to occur in vivo within the woman's body [4] - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States, and it also sells and distributes the INVOcell device to third-party fertility clinics [4] - The IVC procedure is designed to provide a more connected, intimate, and affordable experience compared to traditional ART treatments, potentially delivering comparable results at a lower cost than traditional IVF [4]

As filed with the Securities and Exchange Commission on September 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number ...

As filed with the Securities and Exchange Commission on September 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 Wing Fung Alfred Siu Chief Executive Officer 36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district Watthana District, Bangkok 10110 Thailand Tel: +1 (212) 537-4406 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) B ...

Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]

Core Viewpoint - INVO Fertility, Inc. has received a notice of allowance for a new patent on a modified version of its proprietary INVOcell device, extending intellectual property protection through 2040, which reflects feedback from embryologists to simplify the device's use [1][2][5] Company Overview - INVO Fertility is a healthcare company focused on the fertility sector, dedicated to expanding assisted reproductive technology (ART) care [6] - The company operates two INVO Centers and one IVF clinic in the United States, and engages in the sale and distribution of the INVOcell technology to third-party fertility clinics [6] Product Details - The INVOcell device is the world's first FDA-cleared intravaginal culture (IVC) system, allowing fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [3][4] - The device was originally granted FDA clearance in 2015 and received an update in 2023 to extend the incubation period from 3 days to 5 days [4] - The modified design of the INVOcell device was based on embryologists' feedback, transitioning from a dual-chamber to a singular main chamber [4] Market Position - The INVOcell procedure offers comparable pregnancy rates to traditional IVF while providing a more patient-centered and affordable experience [5][6] - The company believes that the IVC procedure can deliver similar results at a lower cost compared to traditional IVF and is more effective than intrauterine insemination (IUI) [6]